Advanced or Recurrent Endometrial Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Endometrial carcinoma (EC) is the most common gynecologic malignancy that almost every gynecologist will encounter. The most common symptoms are abnormal uterine bleeding and vaginal discharge. Patients with advanced disease may have symptoms similar to those seen with advanced ovarian cancer, such as abdominal or pelvic pain, abdominal distension, early satiety, or a change in bowel or bladder function. Women with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Most patients with endometrial cancer are diagnosed at an early stage (Stage I or II) and have a more favorable prognosis compared with patients diagnosed with advanced (Stage III or IV) disease (5-year survival rates of >74% vs. ≤15%, respectively). Prognosis is also poor for patients with distant recurrent disease (median survival of <5 years).
·
The prevalence of endometrial cancer in the
United States is 25.7/100,000 women per year.
Thelansis’s “Advanced or Recurrent
Endometrial Cancer Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Advanced
or Recurrent Endometrial Cancer treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Advanced or Recurrent Endometrial Cancer across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Advanced or Recurrent Endometrial
Cancer Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment